Abstract
Familial hypercholesterolemia (FH) is an autosomal dominant disease most often caused by mutations in the low-density lipoprotein receptor (LDLR) gene, which consists of 18 exons spanning 45 kb and codes for a precursor protein of 860 amino acids. Mutations in the LDLR gene lead to a reduced hepatic clearance of LDL as well as a high risk of coronary artery disease (CAD) and sudden cardiac death (SCD). Recently, LDLR transgenes have generated interest as potential therapeutic agents. However, LDLR packaging using a lentiviral vector (LVV) system pseudotyped with a vesicular stomatitis virus (VSV)-G envelope is not efficient. In this study, we modified the LVV system to improve transduction efficiency and investigated the LDLR regions responsible for transduction inhibition. Transduction efficiency of 293T cells with a 5′-LDLReGFP-3′ fusion construct was only 1.55% compared to 42.32% for the eGFP construct. Moreover, co-expression of LDLR affected eGFP packaging. To determine the specific region of the LDLR protein responsible for packaging inhibition, we designed constructs with mutations or sequential deletions at the 3′ and 5′ ends of LDLR cDNA. All constructs except one without the ligand-binding domain (LBD) (pWoLBD–eGFP) resulted in low transduction efficiency, despite successful packaging of viral RNA in the VSV envelope, as confirmed through RT-PCR. When we evaluated a direct interaction between LDLR and the VSV envelope glycoprotein using MD simulation and protein–protein interactions, we uncovered Val119, Thr120, Thr67, and Thr118 as exposed residues in the LDLR receptor that interact with the VSV protein. Together, our results suggest that the LBD of LDLR interacts with the VSV-G protein during viral packaging, which significantly reduces transduction efficiency.
Highlights
Familial hypercholesterolemia (FH) is a life-threatening autosomal co-dominant disease with a population prevalence of approximately 1 in 160,000–300,000 [1,2]
We studied the interaction between the low-density lipoprotein receptor (LDLR) ligand-binding domain (LBD) (PDB ID: 1n7d) and vesicular stomatitis virus (VSV) glycoprotein
We used an lentiviral vector (LVV) in combination with the VSV envelope
Summary
Familial hypercholesterolemia (FH) is a life-threatening autosomal co-dominant disease with a population prevalence of approximately 1 in 160,000–300,000 [1,2]. In approximately 90% of patients with FH, the disease results from mutations in the low-density lipoprotein receptor (LDLR), which is responsible for the elimination of LDL-cholesterol (LDL-C) from the blood by endocytosis and intracellular degradation [3]. Mutations in APOB reduce the affinity of the LDLR, whereas gain-of-function mutations in PCSK9 cause high levels of LDLR degradation, because this gene is thought to be involved in the degradation of lysosomal LDLR protein [5]. This degradation results in reduced levels of receptor on the cell surface, and to higher accumulation of LDL-C
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.